Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advisory Committee Unanimously Rejects Sanofi’s Zimulti

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s Endocrinologic and Metabolic Drugs Advisory Committee unanimously votes against approval of Sanofi-Aventis’ rimonabant for a weight loss indication.

You may also be interested in...



GW Succeeding With Cannabinoid Drug This Time Around

Drug candidates targeting the cannabinoid receptors have a spotty past, so GW's successful Phase III data in pediatric epilepsy meets with great investor enthusiasm.

Eric Colman, FDA’s Lead Obesity Drug Reviewer, Dies At Age 53

As a reviewer, team leader and deputy director in the Division of Metabolism and Endocrinology Products, Colman spearheaded the agency’s policy development on weight-management products.

UK’s NICE Proposes Coverage For Troubled Sanofi Obesity Drug Rimonabant

British agency recommends CB-1 receptor antagonist as adjunct to diet and exercise for obese adults intolerant of Xenical, Meridia.

Related Content

Topics

UsernamePublicRestriction

Register

OM009724

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel